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Abstract
Epstein-Barr virus (EBV) infection contributes to the development of different types of
human malignancies, especially nasopharyngeal carcinoma. As a herpesvirus, EBV can
establish two major modes of virus-cell interactions: a latent or a lytic infection. Latent
infection is prevalent in the vast majority of malignant cells in EBV-related malignan‐
cies. Inducing a switch from latent to lytic infection in a substantial fraction of malignant
cells  has  long  been  considered  as  a  potentially  interesting  therapeutic  approach.
Therapeutic benefits are expected from (1) the cytotoxic or cytostatic effects of viral
products expressed in the context of the lytic cycle; (2) expression of viral enzymes
capable of metabolizing pro-drugs selectively inside these cells and (3) broadening the
expression spectrum of antigenic viral proteins. In this chapter, addressing non EBV-
specialized readers, we first summarize the main aspects of EBV biology with emphasis
on the cellular mechanisms known to control latent and lytic infections. Then, we outline
the basic principles and requirements of cytolytic EBV activation performed with a
therapeutic intent. Finally, we review the main categories of pharmacological agents
reported to be active in the switch from latent to lytic infection, including drugs used
for conventional anti-tumour chemotherapy, histone-deacetylase inhibitors and various
miscellaneous compounds.
Keywords: nasopharyngeal carcinoma, Epstein-Barr virus, lytic cycle, histone-deace‐
tylase inhibitors, epigenetics, immunotherapy, phenotypic screening, compound li‐
brary
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1. Introduction
Nasopharyngeal carcinomas (NPCs) are consistently associated with the Epstein-Barr virus
(EBV) [1] and represent a major public health problem worldwide. In order of frequency, it is
the third leading cause of virus-related human malignancies, ranking just behind hepatocellu‐
lar carcinomas linked to the hepatitis B and C viruses and cervix carcinoma involving human
papilloma viruses (HPV) [2]. The incidence of NPC is particularly high in Southern China,
especially in the Guangdong province (approximately 25 cases per 100,000 persons per year).
In addition, there are areas of intermediate incidence in Southeast Asia and North Africa. Men
have been shown to be two to three times more likely to develop NPC than women, the most
frequent age of disease occurrence being 50–60 years. Regardless of patient geographical origin,
NPCs are constantly associated with EBV (except for a very small number of highly differenti‐
ated atypical forms related to tobacco and alcohol and a few cases associated with human
papilloma viruses [HPV] mainly observed in Europe and North America) (reviewed in [3]). Like
other EBV-associated malignancies, NPC is clearly a multifactorial disease. The non-viral risk
factors include germline genetic susceptibility involving alleles of the major histocompatibili‐
ty complex (MHC) region on chromosome 6 [4]. One example of a susceptibility gene not linked
to the MHC region is MST1R. It encodes a protein detected in the ciliated epithelial cells in
normal nasopharyngeal mucosa, which plays a role in the cilia motility, thus being essential for
host defence [5]. The action of diet carcinogens, like salt-preserved fish in South China, probably
accounts for multiple acquired cellular genetic and epigenetic alterations detected in malig‐
nant cells [4].
Investigations on the mechanisms of NPC oncogenesis and novel therapeutic approaches have
long been hampered by a lack of biological resources. It has been proven very difficult to derive
tumour lines propagated in vitro or even patient-derived xenografts (PDXs), which retain the
EBV-genome, using clinical NPC specimens. Currently, there is only one EBV-positive NPC
tumour line (C666-1), which is routinely propagated in vitro, and a small number of EBV-
positive NPC PDXs whose cells are not easily handled in vitro [6–9]. There is evidence that
malignant NPC cells tend to lose the EBV genome when one attempts their propagation in
vitro. The resulting EBV-negative cell lines seem to have a phenotype, which does not fit with
the NPC cell phenotype in situ, especially with regard to immunological characteristics (e.g.,
HONE1) [10]. They are sometimes artificially reinfected by EBV in vitro, but this does not
restore a typical NPC cell phenotype.
In addition to the latent EBV-infection, the malignant phenotype of NPC cells is explained by
a number of genetic and epigenetic alterations. None of these alterations is constant in all NPC
tumours, and few are highly specific of NPCs. In most cases, there are no alterations in the
TP53 gene (it is mutated in less than 10% of the cases; [11]). In contrast, many other tumour
suppressor genes (TSGs) are frequently silenced in NPC cells, especially CDKN2A (chromo‐
some 9p21.3) and RASSF1 (chromosome 3p21.3). Their inactivation often results from a
combination of hemizygous deletion and promoter hypermethylation on the remaining allele.
However, deletions of both alleles and inactivating point mutations have been also reported.
Silencing of these TSGs often occurs very early in the carcinogenic process [12]. Many TSGs
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like the gene encoding the Wnt inhibitory factor 1 (WIF, 12q14.3) or E-cadherin (CDH, 16q22.1)
are consistently inactivated by methylation of both alleles [13, 14]. One has to keep in mind
that prolonged latent—or even transient EBV infection—favours genome-wide hypermethy‐
lation of gene promoters [15]. In addition to the silencing of multiple TSGs, NPC cells exhibit
alterations of multiple oncogenes, which are often affected by copy number gains, especially
CCND1 (encoding cyclin D1 on chromosome 11q13.3) and PIK3CA (3q26.1) [12, 16]. There are
also frequent copy-number gains of the gene encoding the lymphotoxin-β receptor (LTβR) on
chromosome 12p13.31 [12]. This is a rare – or even unique – example of a genetic alteration
which is highly specific of NPC tumours. Two oncogenic fusion genes—UBR5-ZNF423 and
FGFR-TACC3—have been identified by high-throughput sequencing of tumour mRNAs
(RNAseq), but they are only detected in a minority of NPC specimens, mainly among late stage
tumours [17, 18]. Whole exome sequencing of 128 NPC specimens has revealed mutations in
genes encoding proteins involved in chromatin remodelling, especially ARID1a (about 10% of
the specimens) and in the process of DNA methylation (TET1, TET2 and TET3, altogether in
about 9% of the specimens) [11].
On average, NPCs are more radio-sensitive and chemo-sensitive than other head and neck
tumours. However, they still raise serious therapeutic issues: (1) NPCs are often discovered at
a late stage whereas lymph node and distant organ metastases occur early in tumour evolution;
(2) despite remarkable advances in 3D radiotherapy, irradiation often leads to severe func‐
tional sequels (subcutaneous and muscular sclerosis and xerostomia); (3) although metastatic
lesions are initially sensitive to chemotherapy, they often escape from treatment control after
a few months [19, 20]. In summary, despite the remarkable progress achieved in the recent
years, there is still an urgent need for better therapeutic modalities. In this context, the idea of
using EBV as a kind of endogenous oncolytic virus has been in the air for a very long time. The
proof of principle that pharmacological agents can disrupt latent infection and push at least a
fraction of EBV-infected malignant cells towards the reactivation of the viral lytic cycle was
presented almost 40 years ago. Sodium butyrate was reported as a potent activator of the lytic
cycle in EBV-infected human B-lymphocytes in 1979 [21]. However, the progress of this concept
towards therapeutic applications has been very slow, especially regarding NPC. The aim of
this review is to assemble key information for a public of non-EBV-specialists who want to
understand the cellular, molecular and pharmacological basis of translational research on
cytolytic viral activation in nasopharyngeal carcinomas.
2. Main aspects of EBV biology and regulation of the latent/lytic modes of
infection
2.1. General aspects of EBV biology
EBV is one of the eight human Herpesviridae. It belongs to the subfamily of the γ-herpesvirinae
and to the genus of lymphocryptoviruses. Like all Herpesviridae, it is an enveloped double-
stranded DNA virus, containing about 80 genes. It is the causative agent of infectious mono‐
nucleosis, and it has an etiological role in several human malignant diseases mainly of
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lymphoid and epithelial origin as well as several autoimmune diseases. Examples of EBV-
related malignancies are nasopharyngeal carcinomas, several types of lymphomas (endemic
Burkitt’s Lymphoma (BL), more rarely Hodgkin lymphomas, centro-facial NK-T lymphoma,
post-transplant lymphomas and AIDS-associated lymphomas), and approximately 10% of
gastric cancers worldwide [22–25]. Examples of autoimmune diseases likely to involve EBV
are multiple sclerosis and systemic lupus erythematosus [26, 27]. Like all other herpesviruses,
EBV causes lifelong infection following the primo-infection. More than 90% of adult humans
are healthy carriers regardless of their geographic origin. Its persistence in healthy carriers is
Figure 1. EBV-genome structure and configuration in connection with latent or lytic infection: (A) EBV genome map
(linear representation). EBV genome contains about 180 kilobase pairs (kb). Both ends of the viral DNA contain a varia‐
ble number of repeated non-coding sequences of 500 bp (called TR for terminal repeats). In addition, there are internal
repeated sequences called internal repeats (major IR1 and minor IR 2–4). Ori-P is the replication origin of the viral ge‐
nome used in the latent state of infection. The Ori-lyt are two replication origins used during the lytic infection. The
reference restriction map is based on the digestion of the viral DNA by the restriction enzyme BamH1. Restriction frag‐
ments are classified from the largest (BamH1A) to the smallest (BamH1Z). Designation of open-reading frames is
based on this restriction map. For example, BZLF1 is the first leftward open reading frame in the BamH1 Z fragment
(Bam Z leftward open-reading frame 1) (BZLF1 by extension also means the corresponding protein). (B) Configuration
of the EBV genome characteristic of the latently infected cells. When the infected cell enters a state of latent infection
the viral DNA is circularized probably by recombination of the TRs. This circular form of the genome called episome is
contained in the nucleus in combination with cellular chromatin but apart from chromosomes. The episomes are pas‐
sively replicated by cellular DNA polymerases starting from the Ori-P origin of replication. During latent infection,
most viral genes are silent. However, about 10% of them are consistently expressed (in blue). Most of these genes en‐
code final products—viral non-coding RNAs or proteins—with transforming properties. They are called “latent genes”
whereas genes expressed only during lytic infection are called “lytic genes”. There is no topographical separation be‐
tween the two categories of genes.(C) Configuration of the EBV-genome characteristic of the lytic infection. As usual in
virology, the phase of the lytic cycle which precedes viral DNA replication is called the early phase. As soon as the
viral DNA pol starts the autonomous replication of the viral genome, lytically infected cells enter the late phase. Newly
synthesized viral genomes are in a linear configuration. Viral proteins expressed at the very beginning of the early
phase of the lytic cycle like BZLF1 and BRLF1 are encoded by immediate early genes. Early viral proteins are ex‐
pressed at a more advanced stage. Many of them are involved in DNA metabolism, for example, the viral thymidine-
kinase, DNAse and DNA polymerase. The EBV protein kinase (BGLF4; protein encoded by the Bam G leftward open
reading frame 4) can phosphorylate various substrates. It is also one component of the viral particle.
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the result of three types of viral characteristics: (1) its capacity to continuously induce bursts
of productive infections in various tissues, especially in the upper aerodigestive tract and more
specifically in the tonsils, the salivary glands and possibly gingiva; (2) its capacity to achieve
latent infection mainly in B-lymphocytes, especially memory B cells in blood, bone marrow
and lymphoid organs; (3) its sophisticated strategies of immune evasion [28].
The distinction between two major modes of virus-cell interactions is a key to understanding
EBV biology [29]. (1) Latent infections are cellular infection modalities characterized by the
absence of viral particle production, a restricted expression of viral genes (often less than 10
out of 80) and a circular configuration of the viral genome (Figure 1). (2) Lytic/productive
infections are characterized by sequential or concomitant expression of most viral genes,
abundant synthesis of linear viral genomes and finally extracellular release of viral particles
or virions in a context of mandatory cell death.
2.2. Latent EBV infection in LCL and NPC cells
One major common characteristic of most EBV-related malignancies is the predominance of
latent modes of virus-cell interactions. As a rule in EBV-associated tumours, no EBV particles
are detected by electron microscopy on tumour sections, whereas the viral DNA can be
visualized in the nuclei of malignant cells by in situ hybridization. Consistently, very few
malignant cells exhibit expression of viral proteins characteristic of the lytic/productive cycle.
This minimal expression of lytic viral proteins in EBV-infected malignant cells favours immune
evasion. In most latently infected cells, the virus-cell interactions are bidirectional: a few viral
genes often modify the phenotype of the host cell, whereas the cellular context contributes to
the repression of most viral genes (see subsequent section B3). For laboratory investigations,
a model of latent EBV infection is easily obtained in vitro by infection of peripheral blood
mononuclear cells (PBMCs) from normal donors, which results in the oncogenic transforma‐
tion of resting B cells. These EBV-transformed B-cell lines are often called lymphoblastoid cell
lines (LCLs). LCLs are immortalized and tumorigenic in SCID (severe combined immune-
deficiency) mice [30]. They represent a privileged model for in vitro investigations of the
molecular basis of latent infections.
During latency, the viral genome is conserved under the form of circular copies, called
episomes, from one to several tens, which are present in the nuclei apart from the cell chro‐
mosomal DNA but also coated with cellular chromatin and replicated by cellular enzymes at
each cell division. Most viral genes expressed in EBV-associated malignancies belong to the
category of the latent genes, which are expressed in LCLs in vitro and contribute to the
maintenance of the transformed phenotype. Their oncogenic effects are summarized in
Table 1. The latent genes encode nuclear proteins like the EBNAs (Epstein-Barr nuclear
antigens), membrane proteins like LMP1, LMP-2A and LMP-2B (latent membrane proteins 1,
2A and 2B) and non-coding RNAs. There are two main categories of non-coding viral RNAs:
genuine microRNAs and the EBERs (Epstein-Barr virus encoded small RNAs) [31]. Two
families of viral microRNAs, called “BHRF1” and “BART” microRNAs, can be transcribed
from two distinct regions of the EBV genome, the Bam-H1 H and Bam-H1 A segments,
respectively. The BHRF1 (Bam H rightward open reading frame 1) cluster includes at least
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four microRNAs which are transcribed in LCLs but not detectable in most NPC specimens.
They have a key role in the inhibition of apoptosis [32]. In contrast, the microRNAs of the BART
(Bam A rightward transcripts) family are abundant in most NPC cells and not detected in
LCLs. About 40 BART microRNAs have been identified so far [33, 34]. They target a great
variety of mRNAs, for example, those encoding the pro-apoptotic protein Puma (miR-BART5),
the tumour suppressor protein PTEN (miR-BART1) or the viral DNA polymerase (miR-
BART2) [35–37]. The EBERs are single-stranded RNAs of about 170 nucleotides with a complex
secondary structure containing double-stranded segments which can react with various
cellular receptors of double-stranded RNAs such as the PKR (protein-kinase RNA-dependent),
RIG1 (retinoic acid-inducible gene 1) and TLR3 (Toll-like receptor 3) [38]. These interactions
stimulate resistance to interferon and production of growth factors like IGF-1 (insulin-like
growth factor 1) [38].
Type EBV product Examples of functions
Latency
product
Non-coding latent
transcripts
EBERs 1 and 2
(non-coding RNAs)
Inhibit the RNA dependent protein
kinase (PKR) activate the Toll-like
receptor 3 (TLR3) [38]
miR-BART (microRNAs) Inhibit expression of some viral lytic
and cellular pro-apoptotic genes,
promote metastases [35, 37, 42]
Non-membrane
protein
EBNA 1
(nuclear protein)
Episome maintenance, contributes to disruption
of PML bodies [43]
BARF1
(secreted protein)
Ligand of the m-CSF or CSF1 receptor [44]
Membrane latent
protein
LMP1 Activator of Bcl3/p50/P50 NF-kB complex [1]
LMP2A Activator of PI3 kinase/Akt pathway [1]
LMP2B Accelerates the degradation of interferon
receptors [1]
Lytic cycle
products
Immediate early
proteins (IE)
BZLF1 Act as transactivators, enhancing the
expression of later lytic genes [45, 46]BRLF1
Early
proteins (E)
DNA polymerase Lytic replication of the viral genome
EBV-DNase Alkaline nuclease with endonuclease
and exonuclease activities
EBV-thymidine kinase (TK) Phosphokinase with a probable role in
the phosphorylation of FIAU [47, 48]
EBV-protein kinase (PK) Phosphokinase involved in DNA replication
and virion production. Phosphorylates
ganciclovir [49, 50]
Late
proteins (L)
VCA (viral
capsid antigen)
A complex of structural proteins assembled in the
viral capsid
Gp350 Viral envelope glycoprotein binding to the cell
membrane receptor CD21 (also known as CR2) [51]
Table 1. Examples of EBV latency and lytic cycle products with clues on their functions.
Herpesviridae154
In comparison to LCLs, latent EBV infection in NPC cells has some specific features. The
expression of latent viral proteins is more restricted than in LCLs. Only one latent nuclear
protein—EBNA1—is expressed in contrast to six in LCLs. The latent membrane proteins,
LMP1 and LMP2, are present in most tumour specimens but often at a low level and with major
heterogeneity among tumour cells [39, 40]. Another specific feature of latent EBV-infection in
NPCs is the huge abundance of the BART microRNAs which on average account for 20% of
total tumour microRNAs [41]).
2.3. The switch from latency to the lytic/productive infection and its regulation
2.3.1. General features of the switch from latent to lytic EBV-infection
Experimental lytic/productive infections by EBV can be achieved in several manners. As
explained in the previous section, EBV infection of resting B cells in vitro results mostly in
transformed cells, which are latently infected. However, EBV-transformed B cells can enter the
lytic/productive cycle at a secondary stage triggered by plasmacytic differentiation or treat‐
ment with various chemicals (Table 2. The experimental systems used for EBV infection of
epithelial cells in vitro are completely different. First, penetration of viral particles often
requires special procedures, as for example, pre-adsorption on B cells [52]. Next, penetration
of EBV in epithelial cells often results in direct lytic infection (Figure 2) [53, 54]. With most
experimental systems, latently infected epithelial cells remain rare, and their isolation usually
requires the use of recombinant viruses carrying selectable markers [53]. In some models based
on cultured primary epithelial cells, primary lytic infection can be blocked by overexpression
of cyclin D1 or inhibition of CDKN2A. So far, most laboratory investigations on EBV lytic/
productive infection have been done starting from latently infected cells switching to lytic viral
activation (see Figure 2). This switch is triggered by external factors and/or modifications of
physiological cell conditions, for example, differentiation or senescence. It is the result of a
change in the balance of factors either blocking or enhancing the expression of lytic viral genes.
As reviewed by Miller et al [29] and more recently by Kenney et al [46] the switch from latent
to lytic infection is a sequential process, comprising two main sets of events:
1. Upstream events leading to the expression of the immediate early viral transactivators
BZLF1 (also called ZEBRA, Zta or EB-1) and BRLF1 (also called Rta) [29].
2. Downstream events resulting from the interaction of BZLF1 and BRLF1 with a number of
viral promoters controlling genes encoding products of the lytic cycle, such as, the EBV
DNA-polymerase or EBV-TK (thereafter called lytic promoters) [55].
The genes encoding BZLF1 and BRLF1 are themselves under the control of promoter regions
(Zp and Rp), which are regulated by a wide number of cellular factors, either activators or
inhibitors. The influence of the inhibitors is predominant in the latently infected cells and vice
versa during lytic activation.
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Class of drugs Example
Direct PKC activators Phorbol-esters [65]
Conventional chemotherapy [30, 60, 74, 88–90] cis-platinum or cisplatin (alkylating agent); paclitaxel (stabilizer of
mitotic spindle); 5-fluoro-uracil (pyrimidine analog); gemcitabine
(cytidine analog)
Inhibitors of histone deacetylases (HDACi) Sodium butyrate [21],
Trichostatin A [61]
Valproic acid [86–88, 104],
Panobinostat (LBH-589) [94], Vorinostat (SAHA) [95, 96],
Romidepsin [60, 97]
Demethylating agents 5-Azacitidine [100]
Protease inhibitors Bortezomib [47, 48]
Gamma-secretase inhibitors Dibenzazepine [101]
Tetrahydrocarbolines and other compounds
recently selected by high-throughput assays [103],
[102]
Prodrugs activated by EBV enzymes [59, 80, 105] Ganciclovir (9-(1,3-dihydroxy-2-propoxyméthyl) guanine or
DHPG)
FIAU (2′-fluoro-2′-deoxy-β-D-5-iodo-uracil-arabinofuranoside)
[47, 48]
Table 2. Summary of the different drugs with reported capacity of lytic EBV activation and prodrugs phosphorylated
by EBV-encoded kinases.
BZLF1 and BRLF1 activate one another’s promoter and their cooperation is required for
optimal activation of many lytic viral promoters [56]. BZLF1 preferentially activates these
promoters when they are methylated, whereas BRLF1 is more active on unmethylated
promoters [45]. Therefore, they cooperate to induce lytic activation, no matter if the viral
genome is methylated or unmethylated. BRLF1 ability to transactivate its target promoters is
also dependent on another epigenetic mark, which is the 5-hydroxymethylation of cytosine in
promoter CpG islands. Hydroxy-methylation induces an open chromatin conformation, which
is critical for optimal action of BRLF1 but not BZLF1 [56].
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Figure 2. Main modalities of virus-cell interactions in lymphoid and epithelial cells.
– When human resting B-lymphocytes are infected by EBV, a fraction of them enter a state of
viral latency requiring the circularization of the EBV genome and the expression of several
viral latent genes. Simultaneously, the host cell undergoes an oncogenic transformation driven
by the viral latent genes, especially EBNA2, EBNA3A and 3C and LMP1. These transformed
B-cells can proliferate indefinitely resulting in LCLs. However, a secondary switch from
latency to the lytic cycle can occur in a fraction of them. This fraction is generally very small
but it can be increased by some pharmacological agents like HDACi (histone deacetylase
inhibitors) or PKC (protein-kinase C) activators.
– EBV infection of epithelial cells in vitro requires special experimental systems like co-
cultivation with B-cells carrying viral particles . In most of these experiments, penetration of
the viral particles results in infections which are directly cytolytic or abortive. There is evidence
that the same type of events often occur when epithelial cells are infected in situ, for example
in the salivary glands or in the tonsil epithelium (normal epithelial cells are depicted by a cell
shape named “ordinary epithelial cell”) [57, 58].
– However for some reasons, malignant NPC cells undergo a latent infection suggesting a
special type of virus-cell interactions at the initial stage of the malignant cell proliferation.
There is evidence that the precursor cells have premalignant alterations, especially knock-out
of cyclin kinases’ inhibitors which make them resistant to virus-induced senescence (cells with
pre-malignant lesions are depicted by a cell shape named “precursor of NPC cell”). Obvious‐
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ly, this is not sufficient for the establishment of latency since it is difficult to establish latency
in many epithelial cells which are fully transformed and grown in vitro. In latently infected
NPC cells secondary lytic or abortive cycle can occur spontaneously in a small fraction of the
cells. One important aim of cytolytic activation therapy is to dramatically increase the number
of the malignant cells undergoing the lytic cycle.
2.3.2. Overview of the cell physiological conditions and transcription factors involved in the switch from
latent to lytic EBV infection
The factors controlling the switch from latent to lytic infection are numerous. They are intricate
and highly dependent on the cellular context. Figure 3 is intended to give a concise overview
of these factors. As a first approximation, absence of cellular differentiation, cell proliferation,
EMT (epithelial to mesenchymal transition) and inflammation tend to favour the maintenance
of a latent infection. In contrast, cell differentiation, senescence, DNA damage response and
hypoxia favour the entry into the lytic cycle.
Many signalling pathways which favour lytic EBV activation involve protein-kinases C
(PKCs). PKCs phosphorylate hydroxyl groups of serine and threonine in multiple protein
substrates, including MAP kinases and MARCK proteins. They are involved in multiple and
diverse biological processes including transcriptional regulations, cell growth and immune
responses. Physiological activation of “conventional” PKCs (α, β, γ) requires stimulation by
diacylglycerol and calcium, whereas activation of “novel” PKCs (δ, ε, H, Θ) requires only
diacylglycerol. There is evidence for a special contribution of PKCδ to the control of the switch
from latent to lytic infection. For example, as explained in sections C1, D2 and D3, PKCδ plays
a critical role downstream of various pharmacological agents inducing lytic EBV activation
[59–61]. On the contrary, the intracellular form of the cytokine IL-32 has been shown to prevent
lytic activation by sequestration of PKCδ [62]. Several PKC isoforms activate cellular imme‐
diate early proteins, for example, the FOS and EGR1 (early growth response) transcription
Figure 3. Summary of the physiological cell conditions and transcription factors, which modulate the activity of the
BZLF1 (Zp) and BRLF1 (Rp) gene promoters in the context of epithelial cells. Both promoters are under the control of
inhibitory (left side) and activating (right side) factors. Various physiological cell conditions are enumerated outside
the pink circle, whereas the corresponding regulatory proteins are presented inside the pink circle with transcription
factors appearing in bold brown letters. Detailed explanations and references are provided in section B3-2.
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factors, which have specific binding motifs on the Zp and Rp promoters, respectively [63, 64].
For information, phorbol-esters, which have long been known to induce lytic EBV activation
in lymphoid cells, are direct pharmacological agonists of PKCs [65].
The Blimp-1 transcription factor, which is a key player for lymphoid and epithelial cell
differentiation, is a strong inducer of lytic EBV activation, especially in epithelial cells; it
stimulates the expression of both BZLF1 and BRLF1 [66]. TGF-β has been reported to induce
a partial lytic activation in EBV-positive gastric carcinoma cell lines [67]. Various factors, which
antagonize senescence, favour the maintenance of EBV latency. As already mentioned,
overexpression of cyclin-D1 or loss of CDKN2A, which enhances G0/G1 transition in the cell
cycle, prevents lytic activation in some models of EBV latent infection in epithelial cells [53].
Generally speaking, inflammation—for example, inflammation triggered by TNF-α or
interferon-γ—is rather seen as a factor which strengthens EBV latency [68]. Activation of NF-
κB has been reported to stabilize latency in various γ-herpesviruses [69]. Stat3 is also report‐
ed to stabilize latency in EBV-infected cells [63]. However, the influence of inflammatory
factors on EBV latency in NPC cells has not been well documented. The ZEB1/ZEB2 transcrip‐
tion factors, which are known to contribute to the EMT in various cell types, have been proven
to antagonize EBV lytic activation [46]. Finally, there is evidence that ΔNp63 can contribute to
the maintenance of EBV latency. ΔNp63 is a variant of the p63 transcription factor, which is
preferentially expressed in undifferentiated basal epithelial cells [46].
The switch of latent to lytic infection is also triggered by various types of cellular stress and
adaptive responses. Genotoxic stress and DNA damage response have long been known to
favour EBV lytic activation in various cell backgrounds, especially in NPC cells. BRdU
treatment was used in one of the oldest reports on lytic EBV activation achieved in an NPC
model [70]. Ionizing radiations have been shown to induce lytic activation in LCLs [71]. As
explained in details in section D1, many drugs in the arsenal of conventional cancer chemo‐
therapy are inducers of lytic EBV activation in various cellular backgrounds. The ATM (ataxia-
telangiectasia mutated) kinase and to a lesser extent TP53 often play a critical role in the
sequence of events leading from DNA damage to BZLF1 expression [72, 73]. In addition, there
is evidence that ATM is involved in the lytic cascade downstream of BZLF1 [74]. In other
words, ATM is apparently involved in the lytic cascade upstream as well as downstream of
BZLF1 expression. Endoplasmic reticulum stress, which results from large-scale protein
misfolding, has been reported as a condition leading to lytic activation in LCLs [75]. Finally,
the cellular stress resulting from hypoxia was reported to favour the switch from latent to lytic
infection with a role of the HIF1 transcription factor in the activation of the Zp promoter [46].
2.3.3. Epigenetic factors control the switch from latent to lytic EBV infection
This point will be addressed briefly with focus on two epigenetic processes, which are critical
for the switch from latent to lytic EBV infection: DNA methylation and transcriptional control
by microRNAs. We have previously mentioned that BZLF1 preferentially interacts with
methylated lytic promoters, whereas it is the opposite for BRLF1. Therefore, the net impact of
the methylation or the demethylation of the viral genome is not easily predicted and is highly
dependent on the cell background [56]. Recent work has shed some light on the role of cellular
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microRNAs in the maintenance of EBV latency. Members of the miR-200 family, like miR-200b,
target the transcription factors ZEB1 and ZEB2, thus having the ability to reactivate the EBV
lytic gene expression when added to EBV-infected cells [76]. This applies not only to endoge‐
nous microRNAs but also to members of the miR-200 family conveyed by extracellular vesicles,
which can induce lytic EBV activation in recipient cells [77]. In contrast, other microRNAs of
cellular and viral origin have the ability to repress viral reactivation by targeting elements of
its machinery [78].
3. Basic principles and requirements of therapies based on viral cytolytic
activation in EBV-associated malignancies
Like for all Herpesviridae, production of viral particles is automatically associated with the
death of cells infected by EBV. This is the reason why the productive cycle—as opposed to the
state of latent infection—is often called the lytic cycle [29]. With this in mind, for a long time
—going as far as the end of the seventies—many authors have considered reactivation of the
lytic cycle as a possible therapeutic strategy. For a long time, the concept has evolved very
slowly. One hurdle was the fact that the state of latent infection is generally very stable. In
addition, in most cases it is difficult to go beyond partial reactivation with expression of some
proteins of the lytic cycle like the immediate-early BZLF1 transactivator. On the other hand it
was recognized that, in many cases, even partial reactivation is sufficient to block cell
growth [79]. This intrinsic cytotoxic effect of partial reactivation, the possible induction of the
expression of viral enzymes capable to of metabolizing a prodrug and the wish to enlarge the
range of viral targets for the immune system are currently the main incentives to investigate
the induction of the viral lytic activation as a therapeutic approach [30]. One additional
perspective is to use precursors of radio-opaque molecules processed by viral enzymes and
selectively retained in the malignant cells for specific medical imaging [73, 48]. Two EBV-
encoded enzymes are usually cited as having the potential to metabolize and activate
prodrugs: the EBV thymidine kinase (TK) and the EBV protein kinase (PK) encoded by the
BXLF1 and BGLF4 genes, respectively. Ganciclovir (GCV) and acyclovir (ACV) are not
substrates of EBV-TK. Meng et al. have formally demonstrated that among EBV-encoded
kinases, EBV-PK is necessary and sufficient to phosphorylate GCV and ACV [49]. Consistent
data had been previously reported by Gustafson et al [80]. The phosphorylated active forms
of GCV and ACV inhibits cellular and viral replication. Fialuridine or FIAU (2′-fluoro-2′-
deoxy-β-D-5-iodouracil-arabinofuranoside) is also a prodrug activated in EBV-infected cells,
presumably by the EBV-TK, but its use is limited by its hepatic and metabolic toxicity [47, 48,
81]. However, it can be used occasionally, at least in animal models, for imaging purpose.
Indeed, its phosphorylation by EBV-TK results in its selective retention in malignant cells.
Thanks to this property, FIAU can be used for imaging in two ways either as a carrier of iodine
atoms, which are opaque to X-ray or when the cold iodine atoms are substituted by radioac‐
tive isotopes as a tumour-selective radioactive emitter [47, 48, 73].
Induction of the lytic cycle can also have potentially deleterious effects. Several publications
have shown that lytic activation in a small fraction of malignant cells can enhance malignant
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growth [82]. This is probably due to the increased production of inflammatory cytokines,
angiogenic and growth factors in some cells undergoing the lytic cycle [83, 84]. To prevent
these deleterious effects, it is important: (a) to ensure that the lytic cycle activation occurs in a
large fraction of malignant cells and (b) if possible to combine lytic activation with adminis‐
tration of a cytotoxic prodrug, preferably with a bystander effect (see Figure 4).
Figure 4. Importance of combining the induction of the lytic cycle with the administration of prodrugs. From a thera‐
peutic point of view, induction of the lytic cycle has both positive and negative consequences. Positive consequences
are (1) the expression of viral enzymes, which can activate prodrugs specifically in malignant cells and (2) the broaden‐
ing of viral antigen expression, which is expected to facilitate specific recognition and destruction of malignant cells by
the immune system. One potential drawback is an increase in the production of growth factors and angiogenic factors
by malignant cells. Several advantages are expected from the use of a prodrug specifically activated in malignant cells
(e.g., ganciclovir or GCV): (1) rapid pharmacological killing of malignant cells including many cells that would not
undergo a full lytic cycle and therefore would stay alive for a long time in the absence of the prodrug; (2) reduction in
the production of growth and angiogenic factors coming from cells undergoing the lytic cycle; (3) possible bystander
killing of cells resistant to lytic cycle induction, for example, by diffusion of phosphorylated GCV through gap junc‐
tions.
These experimental approaches will be classified in three categories: (1) one based on drugs
used for conventional antitumour chemotherapy; (2) one based on HDAC inhibitors and (3)
finally, a miscellaneous category including various agents from PKC activators to demethy‐
lating agents.
4. Main categories of pharmacological agents with the potential of cytolytic
activation of EBV in the context of NPC cells
4.1. Impact of pharmacological agents used in conventional chemotherapy
A number of drugs used in conventional chemotherapy have the ability to induce the EBV
lytic cycle in various lymphoid or epithelial cell backgrounds. The drugs which are the most
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active in this process—gemcitabine and to a lesser extent doxorubicin, taxol, cis-platinum
(CDDP), 5-fluoro-uracil (5-FU) and methotrexate, have been empirically identified (cis-
platinum and 5-FU are only active in epithelial cells; methotrexate probably only in lym‐
phoid cells) [30, 59, 85]. Regarding NPC cells, initial data on this topic have been published by
Shannon Kenney’s group in 2002. They showed that CDDP, 5-FU and taxol were able to induce
—or to enhance—the expression of the lytic proteins BZLF1, BRLF1 and BMRF1 in a gastric
carcinoma cell line artificially infected by EBV (AGS-EBV) [59]. Simultaneously in cytotoxici‐
ty assays, synergies were found between GCV and cis-platinum or 5-FU. Similar results were
obtained using the xenografted NPC tumour line, C18. De novo expression of BZLF1 and
enhancement of BMRF1 expression were observed after treatment with CDDP or 5-FU. In
addition, there was a synergy in tumour growth inhibition when GCV was combined with
CDDP or 5-FU in intraperitoneal injections to nude mice bearing C18 xenografts. It is note‐
worthy that the same agents had no impact on lytic EBV-protein expression in two other NPC
xenografts, C15 and C17. One specific feature of C18 shared with AGS-EBV is that, even in the
absence of drug treatment, it has a low level of constitutive lytic protein expression. This is not
the case for the two other NPC xenografts ([7] and P. Busson, unpublished data).
Subsequently, regardless of the cell background, gemcitabine has been confirmed as the most
potent inducer of EBV lytic activation among all drugs routinely used in conventional
chemotherapy [30, 73, 86]. Its capacity to contribute to lytic activation in NPC cells has been
well documented by Wildeman et al. (2012) and to a lesser extent by Hsu et al. (2015) [86, 87].
In both cases, induction of lytic activation in the C666-1 cell line was stronger when gemcita‐
bine (in the range of 3 μM in vitro) was combined with valproic acid (in the range of 300 μM
in vitro). Valproic acid is a short chain fatty acid typically used as an anti-epileptic drug, which
behaves, to some extent, as an HDAC inhibitor. Using the gemcitabine/valproic acid combi‐
nation in vitro more than 80% C666-1 cells were positive for BZLF1 by immunofluorescence
[86]. Wildeman’s publication also provided substantial clinical data. Objective tumour
responses were reported for three end-stage NPC patients subjected to a three-drug regimen
combining gemcitabine, valproic acid and GCV [86]. Interestingly, 3 years later, partial tumour
responses were again reported by the same group for five out of eight NPC patients refracto‐
ry to conventional treatments and subjected to the almost same regimen except that GCV was
replaced by valganciclovir [88]. The median survival was 9 months (95% confidence interval
7–17 months).
In some epithelial cell backgrounds, the combination of gemcitabine with an HDAC inhibi‐
tor is not mandatory for induction of the lytic cycle. Using a naturally EBV-infected gastric
carcinoma cell-line, SNU-719, Lee et al. have observed induction of BZLF1 expression by
gemcitabine alone at low concentrations (in the 10 nM range in vitro) [73]. Consistently, they
have observed a synergy of gemcitabine with GCV in the treatment of SCID mice xenograft‐
ed with SNU-719 gastric carcinoma cells. As pointed by the authors, a synergy between GCV
and gemcitabine has also been reported in treatment of non-EBV-related malignant cells but
much higher concentrations of gemcitabine were required (about 10 μM) [73, 89].
The mechanisms of lytic activation induced by drugs of conventional chemotherapy are
complex and probably diverse. In the case of AGS-EBV cells, Kenney’s group has highlight‐
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ed several signalling pathways suspected to link cell response to cis-platinum and 5-FU with
the expression of immediate-early viral proteins: the MAPK/ERK, p38 MAPK and PKCδ
pathways. However, all these data resulted from experiments based on chemical inhibitors.
Therefore, they would probably need verifications by other approaches. As previously
mentioned, endoplasmic reticulum (ER) stress is one possible cell alteration leading to lytic
activation [75]. However, ER stress markers are not modified in gastric carcinoma cells
subjected to lytic activation driven by gemcitabine [73]. Signalling pathways involved in the
response to genotoxic stress seem to contribute more consistently to viral lytic activation,
especially in epithelial cells. In SNU-719 cells, knocking-down expression of ATM and TP53
by RNA-interference antagonizes BZLF1 induction by gemcitabine [73].
4.2. Impact of HDAC inhibitors
Histone deacetylases (HDAC) belong to a class of enzymes that remove acetyl groups from
histones, allowing them to wrap the DNA more tightly and therefore to decrease gene
expression in the corresponding part of the genome. Therefore, depending on the cell context,
HDAC inhibitors (HDACi) lead to transcriptional activation of a fraction of cellular genes,
which are epigenetically silenced. Many HDACi have anti-oncogenic properties. They inhibit
cell proliferation and favour cell cycle arrest, differentiation or apoptosis. These effects are at
least partially related to re-expression of tumour suppressor genes such as CDKN2A or ATM.
Their use for viral lytic induction is based on the assumption that histone acetylation is one
epigenetic mechanism contributing to the silencing of most viral genes in latently infected cells.
In addition, they can have less direct effects by increasing the expression of cellular proteins
involved in the lytic cycle like the ATM kinase.
The first generation of HDACi includes different categories of compounds, for example,
trichostatin A (one member of the hydroxamic acid family) or short chain fatty acids such as
butyrate and valproic acid. As mentioned in the introduction of this chapter, as early as 1979,
sodium butyrate was shown to induce lytic EBV activation in lymphoid cells [21]. At this date,
the capacity of butyrate to inhibit histone deacetylases was not known, and the exact mecha‐
nism of the lytic induction remained raveled. It is noteworthy that, much later, in the years
2000, arginine butyrate was used in combination with GCV by Faller et al. in the first clinical
trial aiming at lytic EBV activation in a group of patients bearing EBV-associated malignan‐
cies. Fifteen patients with refractory EBV-associated lymphoid malignancies were included in
this phase I/II trial. Significant clinical responses were obtained for 10 of them including some
complete clinical and pathological responses, although with important secondary effects [90].
The impact of valproic acid on lytic EBV gene expression has been mentioned in the previ‐
ous part (D1) of this chapter. In contrast with more recent HDACi, very high concentrations
of valproic acid are required for lytic gene induction, often in the range of 300 μM in vitro. In
addition, valproic acid often has limited effects on lytic gene expression when it is not
combined with another drug acting by a distinct mechanism, like gemcitabine. Recent studies
published by G. Miller’s group have shown that valproic acid has more complex biological
effects than other HDACi. In some circumstances, it behaves as an antagonist of other HDACi
and as an inhibitor of EBV lytic reactivation [63, 91]. Trichostatin A has been reported to induce
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EBV lytic activation in an epithelial cell line artificially infected by EBV through pathways
involving activation of the PKCδ and its phosphorylation of the Sp1 transcription factor
(specificity protein 1) [61]. It is noteworthy that trichostatin has also been reported to induce
activation of chromosomally integrated genomes of human herpesvirus 6 (HHV6), at least in
vitro [92, 93].
HDACi of the second generation are compounds, which have been specifically designed to
inhibit HDAC enzymes. They include the hydroxamic acids like vorinostat (suberoyl anilide
hydroxamic acid or SAHA) and panobinostat (LBH589) and benzamides like entinostat
(MS275). Most of them have the ability to inhibit HDAC enzymes of the class I (HDAC-1,
HDAC-2, HDAC-3 and HDAC-8) and class II (HDAC-4, HDAC-5, HDAC-6, HDAC-7,
HDAC-9 and HDAC-10). In 2012, Faller’s group has reported an interesting comparative
investigation of a series of HDACi mainly of the second generation, with an assessment of their
relative strength in the induction of lytic EBV activation in lymphoid cells [94]. The most potent
agent was panobinostat. Entinostat and apicidin, although less effective, were active in the
nanomolar range. Vorinostat, which is active in epithelial cells as mentioned below, was not
active in the panel of lymphoid cells used by the authors. Panobinostat has obtained appro‐
val from the European Medicines Agency and the Food and Drug Administration (USA) for
the treatment of multiple myeloma.
Information on the impact of HDACi on epithelial cells, especially NPC cells, is available in a
series of reports published by A.K.S. Chiang and collaborators from Hong Kong [95, 96]. Hui
et al. reported in 2010 that in AGS-EBV cells, expression of BZLF1, BMRF1 and gp350 and even
production of infectious viral particles were induced by Vorinostat used at μM concentra‐
tions [96]. As in previous studies, it was observed that the AGS-EBV cells had a certain level
of spontaneous lytic activation in basal conditions prior to any drug treatment [59]. It was also
confirmed that Vorinostat was a poor inducer of lytic EBV activation in lymphoid cells in
contrast with data obtained using epithelial cells. In 2012, the same group has reported in vitro
induction by Vorinostat (5 μM) of BZLF1 and BMRF1 but not gp350 in the NPC cell line C666-1.
The induction of BZLF1 in C666-1 cells needed higher concentration of SAHA and a longer
incubation time than for the artificial EBV(+) epithelial cell lines like HK1-EBV and HONE1-
EBV. Nevertheless, induction of BZLF1 was achieved using Vorinostat in vivo by systemic
treatment of C666-1 cells xenografted into nude mice (50 mg/kg, 5 days a week) [95]. Finally,
in a report of 2016, Hui et al. have used a more selective HDACi, a bacterial product called
romidepsin derived from Chromobacterium violaceum [60]. Romidepsin has selective inhibito‐
ry action against class I HDAC enzymes (mainly HDAC-1, HDAC-2 and HDAC-3). Romidep‐
sin was shown to induce BZLF1, BRLF1 and BMRF1 in artificially EBV-infected epithelial cells
using concentrations ranging from 0.5 to 5 nM. In mice xenografted with C666-1 cells,
combined systemic administration of romidepsin (0.375 mg/kg, 2 days a week) and GCV (50
mg/kg, 5 days a week) resulted in a substantial tumour growth reduction [60]. The impact of
romidepsin on lytic protein expression was abrogated by a chemical inhibitor of PKCδ but not
inhibitors of PI3K, MEK, p38 MAPK, JNK. Interestingly lytic activation was not impaired by
an ATM kinase inhibitor in contrast with observations made on SNU-719 gastric carcinoma
cells treated with gemcitabine (see part D1 of this chapter and Lee et al.) [73]. Romidepsin is
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approved by the FDA (Food and Drug Administration) but not the EMA (European Medicines
Agency) for the treatment of cutaneous T-cell lymphomas. Adverse effects are nausea,
vomiting, thrombocytopenia and leucopenia [97]. For future research, data on romidepsin
underline the potential of novel more selective HDACi whose design is based on now-solved
HDAC structures (third generation HDACi, for more information see Stahl et al. [98]).
4.3. Impact of miscellaneous pharmacological agents
In this section, we will briefly introduce other agents that have been used for lytic EBV
activation but less consistently than HDAC inhibitors or conventional anti-cancer agents like
gemcitabine. Phorbol-esters (like 12-O-tetradecanoylphorbol-13-acetate) are compounds,
which activate proteins of the PKC family. In the history of EBV research, they have been
among the first pharmacological agents along with sodium butyrate and BRdU used for
induction of EBV lytic activation. However, to our knowledge, phorbol-esters have not been
used in experiments involving NPC cells [65]. Nevertheless, as previously mentioned, one
protein of the PKC family, PKCδ was reported to contribute to lytic EBV activation induced
in epithelial cells by cis-platinum and 5-FU on the one hand and by romidepsin, an inhibitor
of class I HDAC enzymes, on the other hand (see sections D1 and D2, respectively) [60, 59].
Bortezomib requires a special mention because it has been selected by a systematic screen‐
ing of an FDA library of hundreds of chemical compounds to identify novel inducers of the
lytic cycle (not published data but quoted by [48]). In Burkit lymphoma cells, the effect of
Bortezomib on lytic activation has been reported to be dependent on the b-ZIP transcription
factor C-EBP β (CCAAT/enhancer-binding protein β [99]). Bortezomib has proven to induce
BZLF1 and EBV-TK expression in EBV-positive Burkitt lymphoma or gastric carcinoma cells
xenografted on SCID mice [47, 48]. This process has been exploited for selective accumula‐
tion of FIAU in tumour cells expressing EBV-TK. Either for imaging purpose using this
iodinated compound labelled with [125I] or with therapeutic intent after labelling FIAU with
[131I]. To our knowledge, this approach has not been extended to NPC models. As explained
in section C of this chapter, the use of FIAU in patients is compromised by the risk of acute
metabolic or hepatic toxicity [81]. In more recent publication, the same group was involved in
a new systematic screening of another compound library (John Hopkins Drug Library), which
has identified gemcitabine as the best candidate for combination treatment with GCV [73].
Demethylating agents, especially 5-azacytidine, have been considered as potential inducers of
EBV lytic activation in NPC cells. As reported by Chan et al., eight NPC patients were treated
with 5-aza for one to six cycles: only mild lytic activation was recorded by RT-PCR and
immunohistochemistry of lytic EBV products [100]. This relative weakness of 5-azacytidine
might be explained by some distinct characteristics of BZLF1 and BRLF1 transactivation, which
have been observed in the context of epithelial cells. BZLF1 transactivation of lytic gene
promoters is enhanced by DNA methylation whereas it is the opposite for BRLF1 [45]. This is
bad news for the impact of demethylating agents since cooperation of BZLF1 and BRLF1 is
crucial for the optimal progression of lytic EBV activation.
A Notch2 inhibitor—dibenzazepine—has been shown to induce lytic EBV activation in Burkit
and LCL cells by Giunco et al [101]. According to the authors, this effect depends on the
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downregulation of the BATF transcription factor, which modulates BZLF1 expression. To our
knowledge, lytic induction based on Notch2 inhibitors has not been investigated in NPC cells.
Finally, two groups have recently selected novel inducers of the lytic activation by high-
throughput phenotypic screening from large chemical libraries containing several ten
thousands of compounds [102, 103]. Tikhmyanova et al. have reported five structurally related
tetrahydrocarboline derivatives, which are active in the range of 150–170 nM in various EBV-
positive cell-lines including the C666-1 NPC cell line [103]. Choi et al. have published data on
five novel compounds, which are distinct from PKC agonists and HDACi, one of which
activates the MAPK pathways and bears structural resemblance to iron chelators [102].
5. Conclusions
The idea of inducing EBV lytic activation in malignant NPC cells with a therapeutic intent has
been in the air for more than 30 years [21]. However, this therapeutic approach is still facing
major obstacles. First, there is evidence that EBV latency is heavily locked in NPC cells, and
several locking mechanisms are probably intimately connected with the oncogenic altera‐
tions at the levels of genome, epigenome and cell phenotype. For example, there is evidence
that the wild-type ATM kinase plays a critical role at several steps of lytic EBV activation
(although not under treatment by romidepsin) [60, 72, 74]. In fact, ATM is frequently down‐
regulated in NPC cells [106]. There is also evidence that Stat3 activation prevents EBV lytic
activation. Again, constitutive Stat3 activation is a common feature of malignant NPC cells.
Hydroxy-methylation marks often disappear from the DNA of NPC cells [107, 108]. In a
fraction of tumours, this alteration is a consequence of inactivating mutations in the TET1,
TET2 or TET3 genes [11]. Regardless of its mechanism, the loss of DNA hydroxyl-methyla‐
tion promotes malignant transformation and simultaneously makes the lytic promoters less
sensitive to the action of BRLF1 [56].
Another difficulty is the absence of biomarkers for early identification of NPC tumours that
will be responsive to various agents expected to induce the lytic cycle. We suggest that, in
general, the most sensitive tumours will be those where there is a spontaneous expression of
lytic genes prior to any treatment, a point that would deserve a specific investigation. In spite
of all these difficulties, significant progress has been accomplished. Several objective tumour
responses have been obtained in NPC patients treated with a combination of gemcitabine,
valproic acid and GCV [86, 88]. Since HDACi more effective than valproic acid are now
available, there is room for progress using similar patterns of treatment. At a time when the
success of immunotherapies based on checkpoint inhibitors has a dramatic impact on our
approach of cancer biology and therapy, several authors rightly emphasize the importance of
EBV lytic activation as a mean to increase the antigenicity of malignant cells [109]. This trend
is even stronger since major changes are taking place at the confluence of epigenetics, virology
and tumour immunology: recent publications have shown that demethylating agents can
increase tumour cell antigenicity by removing the inhibition of endogenous retroviruses [110].
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However, combining the inducers of EBV lytic activation with prodrugs specifically activat‐
ed by viral enzymes remains a valuable goal. It is striking that while remarkable progress is
being made concerning lytic inducers, almost nothing seems to happen regarding the prodrug
candidates. So far, most investigators rely on GCV (ganciclovir), which was not designed for
EBV-infected cells but is used by default. Nevertheless, a change seems to be in the air in this
field too. A recent systematic proteomic analysis of EBV-PK substrates has identified hun‐
dreds of cellular proteins involved in DNA damage response, mitosis and cell cycle. More
importantly, in terms of pharmacology, the analysis of the phosphosites of these substrates
reveals a proline-rich motif signature, which will probably be helpful for the design of artificial
substrates [50].
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